Treatment Algorithms with the Oncology Brothers

Along with Emil Lou, MD, PhD, FACP, the Oncology Brothers discuss the current standard of care and treatment landscape for Pancreatic Cancer.

Experts discuss the prostate cancer treatment algorithm, focusing on key decision-making points for optimizing therapy based on patient-specific factors and clinical guidelines.

Rohit Gosain, MD; Rahul Gosain, MD; and Katy Beckermann, MD, PhD, discuss advances in renal cell carcinoma treatment, including adjuvant pembrolizumab following KEYNOTE-564 data, management strategies for localized disease, the impact of immunotherapy–tyrosine kinase inhibitor combination regimens for metastatic renal cell carcinoma, insights from pivotal trials, approaches to therapy sequencing, and the role of next-generation sequencing in personalized care.

The Oncology Brothers, discuss how bladder cancer treatment follows a risk-stratified approach, non–muscle-invasive disease is managed with TURBT and intravesical therapy, muscle-invasive disease requires radical cystectomy with neoadjuvant chemotherapy, and metastatic disease is treated with systemic therapy, including chemotherapy and immunotherapy based on patient fitness and tumor characteristics.

Rohit Gosain MD; Rahul Gosain, MD; and Kevin Kalinsky, MD, discuss an overview of hormone receptor–positive (HR+) breast cancer treatment, treatment of locally advanced diseases, treatment options for metastatic breast cancer, and sequencing treatment for endocrine-resistant disease.

Panelists discuss how HER2-positive (HER2+) breast cancer treatment typically follows a targeted approach combining anti-HER2 therapy (trastuzumab [Herceptin]) with chemotherapy. Early-stage disease utilizes neoadjuvant/adjuvant therapy, whereas metastatic cases may require additional HER2-targeted agents. Treatment plans are individualized based on stage, hormone receptor status, and patient factors.

Panelists discuss how triple-negative breast cancer (TNBC) treatment typically follows a multimodal approach: neoadjuvant chemotherapy for tumors larger than 2 cm or node-positive disease, followed by surgery (lumpectomy or mastectomy). Postsurgery radiation therapy is recommended based on staging. For early-stage TNBC, adjuvant platinum-based chemotherapy and immunotherapy with pembrolizumab may be considered. Metastatic TNBC may receive targeted therapy (PARP inhibitors for BRCA mutations) or immunotherapy based on PD-L1 status.

Rohit Gosain, MD; Rahul Gosain, MD, and Pamela Kunz, MD, explore key aspects of neuroendocrine tumor management, from grading classification and molecular profiling through next-generation sequencing to treatment challenges with somatostatin analogues and therapeutic approaches for well-differentiated grade 3 tumors.

With Eileen O’Reilly, MD, the Oncology Brothers discuss the current treatment landscape of pancreatic cancer.

With Martina Murphy, MD, the Oncology Brothers discuss the current landscape and standard of care regarding ovarian cancer treatment.

Shannon N. Westin, MD, joins the Oncology Brothers to discuss advancements in endometrial cancer treatment.

Jorge Cortes, MD, joins the Oncology Brothers, Rohit Gosain, MD, and Rahul Gosain, MD, to have provide comprehensive insights on the treatment of patients with chronic myeloid leukemia (CML).

Pallawi Torka, MD, joins the Oncology Brothers, Rohit Gosain, MD, and Rahul Gosain, MD, to provide comprehensive insights on treatment practices for follicular and mantle cell lymphoma.

Carla Casulo, MD, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to discuss the treatment algorithm for diffuse large B-cell lymphoma (DLBCL).

Allison Betof Warner, MD, PhD, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to discuss recent advances in melanoma and review current standard-of-care treatment practices.

Patrick Forde, MBBCh, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to discuss treatment practices for patients with early-stage non–small cell lung cancer (NSCLC).

Isabel Preeshagul, DO, MBS, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, for a comprehensive discussion on the treatment of patients with metastatic non–small cell lung cancer who have no actionable mutations in the first-line setting.

Balazs Halmos, MD, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to discuss the treatment algorithm for patients with non–small cell lung cancer with actionable mutations.

Eric Singhi, MD, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to provide comprehensive insights on the treatment algorithm for patients with small cell lung cancer (SCLC).

Naveen Pemmaraju, MD, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to discuss the treatment of patients with myelofibrosis, focusing on diagnostic practices, supportive care, therapies, and adverse event management.

Samer A. Al'Hadidi, MD joins the Oncology Brothers, Rohit Gosain, MD, and Rahul Gosain, MD, to have a comprehensive discussion on the treatment algorithm for relapsed/refractory multiple myeloma.

The Oncology Brothers are joined by Nina Sanford, MD; Jeffrey M. Ryckman, MD; and Harris Chengazi, MD, to discuss the treatment of patients with hepatocellular carcinoma from a multidisciplinary perspective, focusing on radiation oncology and interventional radiology.

Caitlin Costello, MD, discusses the evolution of personalized treatment strategies for newly diagnosed multiple myeloma, comparing past and current treatment landscapes.

Nitin Jain, MD, joins Rohit Gosain, MD, and Rahul Gosain, MD, of Oncology Brothers to discuss treatment sequencing for chronic lymphocytic leukemia, covering both first-line and later-line therapies, while emphasizing the important role of Bruton's tyrosine kinase inhibitors in managing this condition.

Sam Klempner, MD, joins the Oncology Brothers, Rohit Gosain, MD, and Rahul Gosain, MD, to have a comprehensive discussion on treatment paradigms for patients with upper GI malignancies.

Aparna Parikh, MD, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to provide comprehensive insights on the treatment algorithm for colon cancer.

Tanios S. Bekaii-Saab, MD, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to discuss treatment practices for patients with hepatocellular carcinoma.

Karine Tawagi, MD, and Sia Daneshmand, MD, join the Oncology Brothers, Rahul Gosain, MD; and Rohit Gosain, MD, to discuss bladder cancer treatment algorithms.

Sumanta Kumar Pal, MD, FASCO, joins the Oncology Brothers, Rohit Gosain, MD, and Rahul Gosain, MD, to discuss the treatment of patients with kidney cancer and highlight the evolving therapeutic landscape.